7-ethyl Camptothecin is a derivative of camptothecin and an anticancer agent.1,2 It inhibits wild-type but not Gly533 mutant topoisomerase I in RPMI-8402 and CPT-K5 cells, respectively (IC50s = 5.48 and >2,500 nM, respectively).1 7-ethyl Camptothecin is cytotoxic to ADJ/PC6 SN-38-sensitive and PC6/SN2-5H2 SN-38-resistant cells (IC50s = 0.85 and 2.98 nM, respectively). In vivo, 7-ethyl camptothecin (0.25-3 mg/kg per day) increases survival in Ehrlich, MM46, Meth A, L1210, P388, and B16/F10 mouse ascites tumor models.2
1.Yoshikawa, M., Ikegami, Y., Hayasaka, S., et al.Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cellsInt. J. Cancer110(6)921-927(2004) 2.Kunimoto, T., Nitta, K., Tanaka, T., et al.Antitumor activity of a new camptothecin derivative, SN-22, against various murine tumorsJ. Pharmacobiodyn.10(3)148-151(1987)